Inquis Medical announced that it closed a $40 million Series B financing round to support its advanced thrombectomy technology.
Marshall Wace led the oversubscribed funding round. Existing investors ShangBay Capital, Yu Star, EnPointe Ventures and Pierre Lamond all participated.
Menlo Park, California–based Inquis said the funding positions it for significant growth and development as it prepares for commercialisation. The company develops what it describes as next-generation thrombectomy systems, including the flagship Aventus Precision Thrombectomy System.
Related: Bright Uro raises oversubscribed $32M Series A
Aventus features proprietary tissue-sensing technology. It provides operators with real-time information on the tissue composition in contact with the device. The system offers enhanced precision and control during procedures, Inquis said in a news release. Earlier this year, the system won FDA 510(k) clearance along with Inquis’ blood return system for peripheral indications.
Inquis also said it’s nearing completion of enrolment in an FDA investigational device exemption (IDE) trial evaluating pulmonary embolism (PE) patients. The company expects the funds to support the completion of the IDE trial and support preparations for the launch of Aventus in 2025.
“We are thrilled to have successfully secured our Series B funding. This is a strong validation of the confidence investors have in our mission and the potential impact of our innovations,” said Vahid Saadat, co-CEO and co-founder of Inquis Medical.
“This substantial investment from Marshall Wace, along with our existing investors, underscores a strong belief in both our technology and our team,” added Mojgan Saadat, co-CEO and co-founder. “We are excited for the next phase of the company and look forward to enhancing patient care by empowering physicians with our unique technology.”
